Forest Laboratories, Inc. Announces Acquisition From Novexel of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor

NEW YORK--(BUSINESS WIRE)--Forest Laboratories (NYSE:FRX) announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca’s announced acquisition of Novexel, S.A.